BAT 2022
Alternative Names: BAT-2022Latest Information Update: 22 Nov 2022
At a glance
- Originator Bio-Thera Solutions
- Class Antivirals; Bispecific antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 07 Nov 2022 Bio-Thera Solutions completes a phase I trial in COVID-2019 infections (In volunteers) in China (IV) (NCT05518695)
- 27 Sep 2022 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I in COVID-2019 infections released by Bio-Thera Solutions
- 27 Sep 2022 Bio-Thera Solutions completes enrolment in its phase I trial COVID-2019 infections (In volunteers) in China (IV) (NCT05518695)